Advertisement

Topics

Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'

02:00 EDT 14 Mar 2018 | InvestorIdeas

March 14, 2018 (Investorideas.com Newswire) Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm.

Original Article: Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'

NEXT ARTICLE

More From BioPortfolio on "Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...